©2024 Stanford Medicine
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
Not Recruiting
Trial ID: NCT00512083
Purpose
The overall aim of this study is to assess the efficacy and safety of AS1411, over a range of
doses, when combined with cytarabine, in the treatment of patients with primary refractory or
relapsed acute myeloid leukemia (AML).
Official Title
An Open Label Randomized Controlled Dose Escalating Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
Eligibility
Inclusion Criteria:
- primary refractory or relapsed AML
- confirmed diagnosis of AML (de novo or secondary) as defined by WHO classification
(Vardiman 2002)
- aged at least 18 years
Exclusion Criteria:
- initial diagnosis of acute promyelocytic leukemia as defined by
French-American-British criteria (Bennett 1976)
- patient in blast crisis stage of chronic myeloid leukemia
- received high-dose cytarabine (total cumulative dose of >6g/m sq)in last 6 months
- interval of <6 months between first onset of last complete remission and current
relapse
- those with primary refractory leukemia who have received more than three previous
induction cycles
- relapsed patients who have received more than three previous treatment regimens
Intervention(s):
drug: AS1411
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Richa Rajwanshi
6507364031